Brought to you by 
Avalanche Biotechnologies goes public, netting $109mm
06 Aug 2014
Executive Summary
Ophthalmic drug developer Avalanche Biotechnologies Inc. netted $109.1mm in its initial public offering of 6.9mm common shares (including the overallotment) at $17 each. The firm had originally planned to sell 5.4mm shares between $13 and $15.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avalanche Biotechnologies goes public, netting $109mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice